osimertinib
astrazeneca
['osimertinib']
in this large, multi-institutional cohort, histologic trans (16%) and met amp (16%) were the most common resistance mechs to 1l osimertinib on tissue bx. in ctdna, secondary egfr mutations (15%) were the most frequent resistance mechs. #asco23 
A group of EGFR+ lung cancer patients who are resistant to targeted treatment. Sharing support & research news, accelerating research, improving outcomes. #lcsm